Cargando…
Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Springer-Verlag
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2723677/ https://www.ncbi.nlm.nih.gov/pubmed/19609501 http://dx.doi.org/10.1007/s00125-009-1452-2 |
| _version_ | 1782170371391225856 |
|---|---|
| author | Rosenstock, J. Fonseca, V. McGill, J. B. Riddle, M. Hallé, J. P. Hramiak, I. Johnston, P. Davis, M. |
| author_facet | Rosenstock, J. Fonseca, V. McGill, J. B. Riddle, M. Hallé, J. P. Hramiak, I. Johnston, P. Davis, M. |
| author_sort | Rosenstock, J. |
| collection | PubMed |
| description | |
| format | Text |
| id | pubmed-2723677 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2009 |
| publisher | Springer-Verlag |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-27236772009-08-10 Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study Rosenstock, J. Fonseca, V. McGill, J. B. Riddle, M. Hallé, J. P. Hramiak, I. Johnston, P. Davis, M. Diabetologia Letter Springer-Verlag 2009-07-16 2009-09 /pmc/articles/PMC2723677/ /pubmed/19609501 http://dx.doi.org/10.1007/s00125-009-1452-2 Text en © The Author(s) 2009 |
| spellingShingle | Letter Rosenstock, J. Fonseca, V. McGill, J. B. Riddle, M. Hallé, J. P. Hramiak, I. Johnston, P. Davis, M. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study |
| title | Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study |
| title_full | Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study |
| title_fullStr | Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study |
| title_full_unstemmed | Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study |
| title_short | Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study |
| title_sort | similar risk of malignancy with insulin glargine and neutral protamine hagedorn (nph) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2723677/ https://www.ncbi.nlm.nih.gov/pubmed/19609501 http://dx.doi.org/10.1007/s00125-009-1452-2 |
| work_keys_str_mv | AT rosenstockj similarriskofmalignancywithinsulinglargineandneutralprotaminehagedornnphinsulininpatientswithtype2diabetesfindingsfroma5yearrandomisedopenlabelstudy AT fonsecav similarriskofmalignancywithinsulinglargineandneutralprotaminehagedornnphinsulininpatientswithtype2diabetesfindingsfroma5yearrandomisedopenlabelstudy AT mcgilljb similarriskofmalignancywithinsulinglargineandneutralprotaminehagedornnphinsulininpatientswithtype2diabetesfindingsfroma5yearrandomisedopenlabelstudy AT riddlem similarriskofmalignancywithinsulinglargineandneutralprotaminehagedornnphinsulininpatientswithtype2diabetesfindingsfroma5yearrandomisedopenlabelstudy AT hallejp similarriskofmalignancywithinsulinglargineandneutralprotaminehagedornnphinsulininpatientswithtype2diabetesfindingsfroma5yearrandomisedopenlabelstudy AT hramiaki similarriskofmalignancywithinsulinglargineandneutralprotaminehagedornnphinsulininpatientswithtype2diabetesfindingsfroma5yearrandomisedopenlabelstudy AT johnstonp similarriskofmalignancywithinsulinglargineandneutralprotaminehagedornnphinsulininpatientswithtype2diabetesfindingsfroma5yearrandomisedopenlabelstudy AT davism similarriskofmalignancywithinsulinglargineandneutralprotaminehagedornnphinsulininpatientswithtype2diabetesfindingsfroma5yearrandomisedopenlabelstudy |